• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of industry meetings attended within the month

Measure was implemented starting March 2010

Dictionary: Number of industry meetings held, including face-to-face meetings and meetings held over the telephone, within the month that OBP participated in. These meeting facilitate communication with industry to help ensure appropriate product development.


These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2010

Skip graphic and jump to text data

Measure was implemented starting March 2010

TimeTargetNumber
Oct 2009N/AN/A
Nov 2009N/AN/A
Dec 2009N/AN/A
Jan 2010N/AN/A
Feb 2010N/AN/A
Mar 2010N/A30
Apr 2010N/A22
May 2010N/A17
Jun 2010N/A23
Jul 2010N/A16
Aug 2010N/A20
Sep 2010N/A28

Number of OBP-managed product quality meetings, held with industry within the month

Dictionary: Number of OBP-managed product quality meetings, including teleconferences and in-person meetings, held with industry within the month. These meeting facilitate communication with industry to help ensure appropriate product development. However they are focused on product quality, manufacturing and related safety issues.

Fiscal Year - 2010

Skip graphic and jump to text data

TimeTargetNumber
Oct 2009N/A5
Nov 2009N/A3
Dec 2009N/A3
Jan 2010N/A7
Feb 2010N/A4
Mar 2010N/A4
Apr 2010N/A9
May 2010N/A4
Jun 2010N/A4
Jul 2010N/A3
Aug 2010N/A1
Sep 2010N/A4

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.